{"product_id":"memorial-sloan-kettering-cancer-center-foundations-in-immunotherapy-in-the-oncology-population-2026","title":"Memorial Sloan Kettering Cancer Center Foundations in Immunotherapy in the Oncology Population 2026","description":"\u003cul\u003e\n  \u003cli\u003eTarget Audience: oncologists\u003c\/li\u003e\n  \u003cli\u003eSample video: contact me for sample video\u003c\/li\u003e\n  \u003cli\u003eInformation:\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e1. Overview\u003c\/p\u003e\n\u003cp\u003eThe Memorial Sloan Kettering Cancer Center Foundations in Immunotherapy in the Oncology Population 2026 course provides a comprehensive exploration of the principles, clinical applications, and management of immuno-oncology therapies. The program covers checkpoint inhibitors, CAR T-cell therapy, and bispecific agents across various malignancies, while offering evidence-based strategies for recognizing and mitigating immune-related adverse events.\u003c\/p\u003e\n\u003cp\u003eImmunotherapeutics have transformed the treatment landscape for patients with both solid tumors and hematologic malignancies. Since the landmark approval of ipilimumab, rapid and ongoing advancements in immunotherapy have continued to revolutionize clinical practice.\u003c\/p\u003e\n\u003cp\u003eThe goal of this program is to improve patient outcomes by advancing understanding of cancer immunology and enhancing the effective, evidence-based application of immunotherapeutic strategies in clinical practice.\u003c\/p\u003e\n\u003cp\u003eSpecialties\u003c\/p\u003e\n\u003cp\u003eSpecialties – Dermatology, Genitourinary Oncology, Hematology, Hepatology, Hospitalist, Immunotherapy, Leukemia, Lymphoma, Medical Oncology, Myeloma, Neuro-Oncology, Nurse Practitioner, Physician Assistant, Pulmonary Medicine, Solid Tumor Oncology\u003c\/p\u003e\n\u003cp\u003e2. Learning Objectives\u003c\/p\u003e\n\u003cp\u003eIdentify and define foundational concepts of immunotherapy, including key immune system components, mechanisms of action, and types of immunotherapeutic agents.\u003c\/p\u003e\n\u003cp\u003eExplain the biological rationale and mechanisms by which immunotherapy targets solid and hematologic malignancies, distinguishing between innate and adaptive immune responses.\u003c\/p\u003e\n\u003cp\u003eApply evidence-based immunotherapeutic approaches to the management of solid tumors and hematologic cancers, including appropriate patient selection, risk stratification, and development of individualized treatment plans.\u003c\/p\u003e\n\u003cp\u003eCompare and contrast novel immunotherapy agents, including checkpoint inhibitors, bispecific antibodies, and immune agonists, in terms of efficacy, safety profiles, and mechanisms of action.\u003c\/p\u003e\n\u003cp\u003eEvaluate the role of CAR T-cell therapy in current oncology practice, including patient eligibility, response rates, and long-term outcomes, and design a toxicity management plan for immune-related adverse events (irAEs) in immuno-oncology patients.\u003c\/p\u003e\n\u003cp\u003e3. Target Audience\u003c\/p\u003e\n\u003cp\u003eBest for oncologists and specialized nursing professionals who want foundational updates on immunotherapy protocols and adverse event management.\u003c\/p\u003e\n\u003cp\u003e4. Topics\u003c\/p\u003e\n\u003cp\u003eAdvancing CAR T-Cell Strategies and Combination Therapies to Improve Outcomes in Gynecologic Malignancies\u003c\/p\u003e\n\u003cp\u003eAdvancing Leukemia Care Through Immuno-Oncology\u003c\/p\u003e\n\u003cp\u003eApproaches to Immunotherapy-related Pneumonitis Management\u003c\/p\u003e\n\u003cp\u003eBreast Oncology- Using cfDNA to Forecast Immunotherapy Treatment Outcomes\u003c\/p\u003e\n\u003cp\u003eCheckpoint Inhibition as a Therapeutic Approach in Advanced Hodgkin Lymphoma\u003c\/p\u003e\n\u003cp\u003eClinical Approaches to Dermatologic Toxicity in Checkpoint Inhibitor Therapy\u003c\/p\u003e\n\u003cp\u003eDiscussion of Novel Checkpoint Inhibitors and Combination Therapy\u003c\/p\u003e\n\u003cp\u003eDostarlimab in MSI-High Gastrointestinal Cancers- Latest Data, Expansion Cohorts, and Basket Trial Insights\u003c\/p\u003e\n\u003cp\u003eEvolving Treatment Paradigms- Immunotherapy in Advanced Bladder Cancer\u003c\/p\u003e\n\u003cp\u003eIL-2-Stimulating Agents from Early Drug Development\u003c\/p\u003e\n\u003cp\u003eInnovations in Small Cell Lung Cancer- DLL3 Agents and Adjuvant Durvalumab\u003c\/p\u003e\n\u003cp\u003eIntrathecal Immunotherapy- A Novel Path in Treating Leptomeningeal Disease no video\u003c\/p\u003e\n\u003cp\u003eMelanoma Subtypes are a Microcosm for Immune Checkpoint Blockade Efficacy Across Oncology-\u003c\/p\u003e\n\u003cp\u003eNeurotoxicity in CAR T-Cell Therapy- Recognition and Management\u003c\/p\u003e\n\u003cp\u003eOverview of Adverse Events in the Cell Therapy Patient- A Discussion of CRS, ICANS, and Prolonged Cytopenias\u003c\/p\u003e\n\u003cp\u003eQ\u0026amp;A and Discussion – 01\u003c\/p\u003e\n\u003cp\u003eQ\u0026amp;A and Discussion – 02\u003c\/p\u003e\n\u003cp\u003eQ\u0026amp;A and Discussion – 03\u003c\/p\u003e\n\u003cp\u003eQ\u0026amp;A and Discussion – 04\u003c\/p\u003e\n\u003cp\u003eQ\u0026amp;A and Discussion\u003c\/p\u003e\n\u003cp\u003eTargeting Multiple Myeloma with Bispecific Immune-Modulating Agents\u003c\/p\u003e\n\u003cp\u003eThe Role of T-Cell Therapy in Standard Care for Synovial Sarcoma\u003c\/p\u003e\n\u003cp\u003eUnderstanding Chimeric Antigen Receptor (CAR) T-Cell Therapy\u003c\/p\u003e","brand":"Medicalcoursespro","offers":[{"title":"Default Title","offer_id":46405744230596,"sku":null,"price":45.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0751\/7644\/4100\/files\/Memorial-Sloan-Kettering-Cancer-Center-Foundations-in-Immunotherapy-in-the-Oncology-Population-2026.jpg?v=1784215535","url":"https:\/\/medicalcoursespro.com\/products\/memorial-sloan-kettering-cancer-center-foundations-in-immunotherapy-in-the-oncology-population-2026","provider":"Medicalcoursespro","version":"1.0","type":"link"}